Yanan Zhu
Stock Analyst at Wells Fargo
(4.70)
# 782
Out of 5,004 analysts
438
Total ratings
42.3%
Success rate
18.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Reiterated: Buy | $55 → $65 | $32.99 | +97.03% | 3 | Sep 9, 2026 | |
| QURE uniQure | Reiterated: Buy | $60 → $75 | $38.32 | +95.72% | 28 | Sep 3, 2026 | |
| SCTX Scribe Therapeutics | Reiterated: Buy | $60 | $21.61 | +177.65% | 2 | Aug 31, 2026 | |
| SYRE Spyre Therapeutics | Reiterated: Buy | $115 | $87.09 | +32.05% | 16 | Aug 25, 2026 | |
| IONS Ionis Pharmaceuticals | Reiterated: Buy | $95 | $43.81 | +116.85% | 46 | Aug 14, 2026 | |
| RNA Atrium Therapeutics | Reiterated: Buy | $25 | $8.19 | +205.25% | 3 | Aug 14, 2026 | |
| ENGN enGene Therapeutics | Rated: Hold | $2 | $1.92 | +4.17% | 19 | Aug 12, 2026 | |
| MGX Metagenomi Therapeutics | Rated: Buy | $9 → $7 | $1.15 | +508.70% | 15 | Aug 11, 2026 | |
| ONC BeOne Medicines AG | Reiterated: Buy | $400 | $359.97 | +11.12% | 3 | Aug 6, 2026 | |
| SRPT Sarepta Therapeutics | Reiterated: Buy | $38 | $18.39 | +106.63% | 16 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 | $24.66 | +183.86% | 23 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $75 | $55.70 | +34.65% | 16 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.1471 | - | 22 | Jun 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $15 | $12.16 | +23.36% | 26 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $95 → $105 | $65.66 | +59.91% | 2 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $4.79 | +129.65% | 28 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $22.74 | +97.89% | 4 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4 | $2.75 | +45.45% | 25 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $14.12 | +41.64% | 26 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $10.80 | +29.63% | 27 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.91 | +161.78% | 19 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4 | $1.43 | +179.72% | 9 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2.5 | $2.33 | +7.30% | 12 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.5 → $1 | $0.023 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $11 → $0.1 | $0.0001 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $2.80 | n/a | 13 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $24.12 | n/a | 7 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $45 → $30 | $1.13 | n/a | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $272 → $326 | $962.22 | n/a | 4 | Feb 2, 2021 |
Pharvaris
Sep 9, 2026
Reiterated: Buy
Price Target: $55 → $65
Current: $32.99
Upside: +97.03%
uniQure
Sep 3, 2026
Reiterated: Buy
Price Target: $60 → $75
Current: $38.32
Upside: +95.72%
Scribe Therapeutics
Aug 31, 2026
Reiterated: Buy
Price Target: $60
Current: $21.61
Upside: +177.65%
Spyre Therapeutics
Aug 25, 2026
Reiterated: Buy
Price Target: $115
Current: $87.09
Upside: +32.05%
Ionis Pharmaceuticals
Aug 14, 2026
Reiterated: Buy
Price Target: $95
Current: $43.81
Upside: +116.85%
Atrium Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $25
Current: $8.19
Upside: +205.25%
enGene Therapeutics
Aug 12, 2026
Rated: Hold
Price Target: $2
Current: $1.92
Upside: +4.17%
Metagenomi Therapeutics
Aug 11, 2026
Rated: Buy
Price Target: $9 → $7
Current: $1.15
Upside: +508.70%
BeOne Medicines AG
Aug 6, 2026
Reiterated: Buy
Price Target: $400
Current: $359.97
Upside: +11.12%
Sarepta Therapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: $38
Current: $18.39
Upside: +106.63%
Aug 5, 2026
Reiterated: Buy
Price Target: $70
Current: $24.66
Upside: +183.86%
Aug 5, 2026
Reiterated: Hold
Price Target: $75
Current: $55.70
Upside: +34.65%
Jun 25, 2026
Rated: Hold
Price Target: n/a
Current: $0.1471
Upside: -
May 12, 2026
Reiterated: Hold
Price Target: $15
Current: $12.16
Upside: +23.36%
May 7, 2026
Reiterated: Buy
Price Target: $95 → $105
Current: $65.66
Upside: +59.91%
May 7, 2026
Reiterated: Buy
Price Target: $11
Current: $4.79
Upside: +129.65%
Apr 2, 2026
Reiterated: Buy
Price Target: $45
Current: $22.74
Upside: +97.89%
Mar 10, 2026
Reiterated: Hold
Price Target: $4
Current: $2.75
Upside: +45.45%
Mar 4, 2026
Reiterated: Buy
Price Target: $20
Current: $14.12
Upside: +41.64%
Feb 25, 2026
Reiterated: Buy
Price Target: $14
Current: $10.80
Upside: +29.63%
Jan 14, 2026
Reiterated: Buy
Price Target: $5
Current: $1.91
Upside: +161.78%
Jan 13, 2026
Reiterated: Hold
Price Target: $4
Current: $1.43
Upside: +179.72%
Jan 5, 2026
Reiterated: Hold
Price Target: $2.5
Current: $2.33
Upside: +7.30%
May 14, 2025
Reiterated: Hold
Price Target: $1.5 → $1
Current: $0.023
Upside: n/a
May 14, 2025
Downgraded: Hold
Price Target: $11 → $0.1
Current: $0.0001
Upside: n/a
May 6, 2025
Reiterated: Buy
Price Target: $10
Current: $2.80
Upside: n/a
May 16, 2024
Rated: Hold
Price Target: n/a
Current: $24.12
Upside: n/a
Aug 16, 2023
Reiterated: Hold
Price Target: $45 → $30
Current: $1.13
Upside: n/a
Feb 2, 2021
Reiterated: Hold
Price Target: $272 → $326
Current: $962.22
Upside: n/a